Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

Michael Markmiller was in excruciating pain for years. The 53-year-old couldn’t walk more than 100 meters without his legs going numb or stand up straight without sharp pains going down his legs.

Red was the hue du jour donned by the staff and residents at Essex Center this week as they participated in a jumping jacks competition among Centers Health Care facilities as part of a comprehensive ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

Researchers analyzed global trends in multidrug-resistant tuberculosis (MDR-TB) among children and adolescents, revealing rising incidence rates, gender disparities, and the disproportionate ...

I am a 67-year-old male with generally good vision. I have had a few floaters in my eyes over the years, but they have generally been small ...

There is currently no schedule data. The Schedule Release will be available on April.

Jan. 29, 2025 — Study finds three new safe and effective drug regimens to fight multidrug-resistant TB. The treatments, which include recently discovered TB drugs, give new options for shorter ...